Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine.
Missale
C
C
Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Italy.
Losa
M
M
Boroni
F
F
Giovanelli
M
M
Balsari
A
A
Spano
P F
PF
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001971:Bromocriptine / Q000008:administration & dosage; D002455:Cell Division / Q000187:drug effects; D004298:Dopamine / Q000494:pharmacology; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009414:Nerve Growth Factors / Q000008:administration & dosage; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000097:blood / Q000188:drug therapy*; D012680:Sensitivity and Specificity
D009414:Nerve Growth Factors; D001971:Bromocriptine; D011388:Prolactin; D004298:Dopamine